Skip to main content
SpringerLink
Log in

Management of Infections in Leukemia and Lymphoma

  • Chapter
Clinical Approach to Infection in the Compromised Host

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chilcote RR, Baehner RL, Hammond D: Septicemia and meningitis in children splenectomized for Hodgkin’s disease. N Engl J Med 295(15):798–800, 1976.

    CAS  PubMed  Google Scholar 

  2. Winston DJ, Schiffman G, Wang DC, Feig SA, Lin CH, Marso EL, Ho WG, Young LS, Gale RP: Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 91(6):835–841, 1979.

    CAS  PubMed  Google Scholar 

  3. Armstrong D, Young LS, Meyer RD, Blevins AH: Infectious complications of neoplastic disease. Med Clin North Am 55(3): 729–745, 1971.

    CAS  PubMed  Google Scholar 

  4. Goldschmidt MC, Bodey GP: Effect of chemotherapeutic agents upon microorganisms isolated from cancer patients. Antimicrob Agents Chemother 1(4):348–353, 1972.

    CAS  PubMed  Google Scholar 

  5. Schabel FM, Pittillo RF: Screening for and biological characterizations of anti-tumor agents using microorganisms. Adv Appl Microbiol 3:223–256, 1961.

    CAS  PubMed  Google Scholar 

  6. Miller SP, Shanbrom E: Infectious syndromes of leukemia and lymphomas. Am J Med Sci 246:420–428, 1963.

    CAS  PubMed  Google Scholar 

  7. Malech HL, Gallin JI: Current concepts: Immunology. Neutrophils in human diseases. N Engl J Med 317(11):687–694, 1987.

    CAS  PubMed  Google Scholar 

  8. Cline MJ: Defective mononuclear phagocyte function in patients with myelomonocytic leukemia and in some patients with lymphoma. J Clin Invest 52(9):2185–2190, 1973.

    CAS  PubMed  Google Scholar 

  9. Lehrer RI, Cline MJ: Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancera. Cancer 27: 1211–1217, 1972.

    Google Scholar 

  10. Baehner RL, Neiburger RG, Johnson DE, Murrmann SM: Transient bactericidal defect of peripheral blood phagocytes from children with acute lymphoblastic leukemia receiving craniospinal irradiation. N Engl J Med 289(23):1209–1213, 1973.

    CAS  PubMed  Google Scholar 

  11. Meyer RD, Young LS, Armstrong D, Yu B: Aspergillosis complicating neoplastic disease. Am J Med 54(1):6–15, 1973.

    Article  CAS  PubMed  Google Scholar 

  12. Epstein SM, Verney E, Miale TD, Sidransky H: Studies on the pathogenesis of experimental pulmonary aspergillosis. Am J Pathol 51(5):769–788, 1967.

    CAS  PubMed  Google Scholar 

  13. Young LS, Meyer RD, Armstrong D: Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med 79(4):518–527, 1973.

    CAS  PubMed  Google Scholar 

  14. Wollman MW, Young LS, Haghbin M: Anti-Pseudomonas heat-stable opsonins in acute lymphoblastic leukemia of childhood. J Pediatr 86:376–381, 1975.

    CAS  PubMed  Google Scholar 

  15. Morrison VA: The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25(1):98–106, 1998.

    CAS  PubMed  Google Scholar 

  16. Forsgren A, Schmeling D, Banck G: Effect of antibiotics on chemotaxis of human polymorphonuclear leukocytes in vitro. Infection 6:S102–S106, 1978.

    Google Scholar 

  17. Björksten B, Ray C, Quie PG: Inhibition of human neutrophil chemotaxis and chemiluminescence by amphotericin B. Infect Immun 14(1):315–317, 1976.

    PubMed  Google Scholar 

  18. Lehrer RI: Inhibition by sulfonamides of the candidacidal activity of human neutrophils. J Clin Invest 50(12):2498–2505, 1971.

    CAS  PubMed  Google Scholar 

  19. King GW, Yanes B, Hurtubise PE, Balcerzak SP, LoBuglio AF: Immune function of successfully treated lymphoma patients. J Clin Invest 57(6):1451–1460, 1976.

    CAS  PubMed  Google Scholar 

  20. Young RC, Corder MP, Haynes HA, DeVita VT: Delayed hypersensitivity in Hodgkin’s disease. A study of 103 untreated patients. Am J Med 52(l):63–72, 1972.

    CAS  PubMed  Google Scholar 

  21. Steigbigel RT, Lambert LH Jr, Remington JS: Polymorphonuclear leukocyte, monocyte, and macrophage bactericidal function in patients with Hodgkin’s disease. J Lab Clin Med 88(l):54–62, 1976.

    CAS  PubMed  Google Scholar 

  22. Sheagren NJ, Block JB, Wolff SM: Reticuloendothelial system phagocytic function in patients with Hodgkin’s disease. J Clin Invest 46:855–862, 1967.

    CAS  PubMed  Google Scholar 

  23. Ward PA, Berenberg JL: Defective regulation of inflammatory mediators in Hodgkin’s disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med 290(2):76–80, 1974.

    CAS  PubMed  Google Scholar 

  24. Brown RS, Haynes HA, Foley HT: Hodgkin’s disease: Immunologic, clinical and histologic features in 50 untreated patients. Ann Intern Med 67:291–300, 1967.

    CAS  PubMed  Google Scholar 

  25. Weitzman SA, Aisenberg AC, Siber GR, Smith DH: Impaired humoral immunity in treated Hodgkin’s disease. N Engl J Med 297(5):245–248, 1977.

    CAS  PubMed  Google Scholar 

  26. Levine AS, Schimpff SC, Graw RG Jr, Young RC: Hematologic malignancies and other marrow failure states: Progress in the management of complicating infections. Semin Hematol 11(2): 141–202, 1974.

    CAS  PubMed  Google Scholar 

  27. Hersh EM, Bodey GP, Nies BA: Cause of death in acute leukemia. JAMA 193:105–109, 1965.

    CAS  PubMed  Google Scholar 

  28. Viola MV: Acute leukemia and infection. JAMA 201:923–928, 1967.

    Article  CAS  PubMed  Google Scholar 

  29. Hughes WT: Fatal infections in childhood leukemia. Am J Dis Child 122(4):283–287, 1971.

    CAS  PubMed  Google Scholar 

  30. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ: Causes of death in adults with acute leukemia. Medicine 55(3):259–268, 1976.

    CAS  PubMed  Google Scholar 

  31. Casazza AR, Duvall CP, Carbone PP: Summary of infectious complications occurring in patients with Hodgkin’s disease. Cancer Res 26(6):1290–1296, 1966.

    CAS  PubMed  Google Scholar 

  32. Feld R, Bodey GP: Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39(3): 1018–1025, 1977.

    CAS  PubMed  Google Scholar 

  33. Notter DT, Grossman PL, Rosenberg SA, Remington JS: Infections in patients with Hodgkin’s disease: A clinical study of 300 consecutive adult patients. Rev Infect Dis 2(5):761–800, 1980.

    CAS  PubMed  Google Scholar 

  34. Bodey GP, Rodriguez V, Valdivieso M, Feld R: Amikacin for treatment of infections in patients with malignant diseases. J Infect Dis 134(Suppl):S421–S427, 1976.

    PubMed  Google Scholar 

  35. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee.American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655, 1992.

    CAS  PubMed  Google Scholar 

  36. Burke PJ, Braine HG, Rathbun HK, Owens AH Jr: The clinical significance and management of fever in acute myelocytic leukemia. Johns Hopkins Med J 139(1):1–126, 1976.

    CAS  PubMed  Google Scholar 

  37. Young LS: Nosocomial infections in the immunocompromised adult. Am J Med 70(2):398–404, 1981.

    Article  CAS  PubMed  Google Scholar 

  38. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25(3):551–573, 1997.

    CAS  PubMed  Google Scholar 

  39. Wade JC, Schimpff SC, Newman KA, Former CL, Standiford HC, Wiernik PH: Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 71(6):983–990, 1981.

    Article  CAS  PubMed  Google Scholar 

  40. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 119(7 Pt l):584–593, 1993.

    Google Scholar 

  41. Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, Viot M, Soler-Michel P, Rollin C, Gres JJ: Cefepime versus imipenemcilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 42(4):511–518, 1998.

    Article  CAS  PubMed  Google Scholar 

  42. Young LS: Amikacin: Experience in a comparative clinical trial with gentamicin in leukopenic subjects. In Luthy R, Siegenthaler W (eds): Current Chemotherapy. American Society for Microbiology, Washington, DC, 1978, pp. 246–248.

    Google Scholar 

  43. Silver RT, Utz JP, Frei E: Fever, infection and host resistance in acute leukemia. Am J Med 24:25–39, 1958.

    Article  CAS  PubMed  Google Scholar 

  44. Goodall PT, Vosti KL: Fever in acute myelogenous leukemia. Arch Intern Med 135(9):1197–1203, 1975.

    Article  CAS  PubMed  Google Scholar 

  45. Boggs DR, Frei III E: Clinical studies of fever and infection in cancer. Cancer 13:1240–1253, 1960.

    Google Scholar 

  46. Atkinson K, Kay HE, McElwain TJ: Fever in the neutropenic patient. Br Med J 3(924):160–161, 1974.

    CAS  PubMed  Google Scholar 

  47. Krick JA, Remington JS: Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol 5(2):249–310, 1976

    CAS  PubMed  Google Scholar 

  48. Israelski DM, Remington JS: Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis 13:322–356, 1993.

    CAS  PubMed  Google Scholar 

  49. Wade JC, Schimpff SC, Newman KA, Wiernik PH: Staphylococcus epidermidis: An increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97(4):503–508, 1982.

    CAS  PubMed  Google Scholar 

  50. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA: Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108(l):30–35, 1988.

    CAS  PubMed  Google Scholar 

  51. Dybedal I, Lamvik J: Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with Streptococcus viridans. Eur J Haematol 42(4):405–406, 1989.

    CAS  PubMed  Google Scholar 

  52. Fowler VG, Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, Gottlieb G, McClelland RS, Corey GR: Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients. Clin Infect Dis 27(3):478–486, 1998.

    PubMed  Google Scholar 

  53. Elting LS, Rubenstein EB, Rolston KV, Bodey GP: Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259, 1997.

    CAS  PubMed  Google Scholar 

  54. Bodey GP, Rodriguez V, Chang HY, Narboni G: Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 41(4):1610–1622, 1978.

    CAS  PubMed  Google Scholar 

  55. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL: Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115(8):585–590, 1991.

    CAS  PubMed  Google Scholar 

  56. Armstrong D: Infectious complications of lymphosarcoma. In Molander DW (ed): Lymphoproliferative Diseases. Charles C. Thomas, Springfield, IL, 1975, pp. 94–109.

    Google Scholar 

  57. Walzer PD, Perl DP, Krogstad DJ: Pneumocystis carinii pneumonia in the United States: Epidemiologic, diagnostic, and clinical features. In Symposium on Pneumocystis carinii Infection. NCI Monograph 43. National Cancer Institute, Bethesda, 1976, pp. 55–63.

    Google Scholar 

  58. Cohen J, Pinching AJ, Rees AJ: Infections and immunosuppression: A study of infective complications of 75 patients with immunologically mediated disease. Q J Med 51:1–15, 1982.

    CAS  PubMed  Google Scholar 

  59. Kaplan MH, Rosen PP, Armstrong D: Cryptococcosis in a cancer hospital: Clinical and pathological correlates in forty-six patients. Cancer 39(5):2265–2274, 1977.

    CAS  PubMed  Google Scholar 

  60. Kaplan MH, Armstrong D, Rosen P: Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 33(3):850–858, 1974.

    CAS  PubMed  Google Scholar 

  61. Horsburgh CR Jr, Feldman S, Ridzon R: Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 31(3):633–639, 2000.

    PubMed  Google Scholar 

  62. Wilson JF, Marsa GW, Johnson RE: Herpes zoster in Hodgkin’s disease. Clinical, histologic, and immunologic correlations. Cancer 29(2):461–465, 1972.

    CAS  PubMed  Google Scholar 

  63. Feldman S, Hughes WT, Kim HY: Herpes zoster in children with cancer. Am J Dis Child 126(2):178–184, 1973.

    CAS  PubMed  Google Scholar 

  64. Schimpff SC, O’Connell MJ, Greene WH, Wiernik PH: Infections in 92 splenectomized patients with Hodgkin’s disease. A clinical review. Am J Med 59(5):695–701, 1975.

    Article  CAS  PubMed  Google Scholar 

  65. Sokal JE, Firat D: Varicella zoster infection in Hodgkin’s disease. Clinical and epidemiological aspects. Am J Med 39:452–463, 1965.

    Article  CAS  PubMed  Google Scholar 

  66. Reboul F, Donaldson SS, Kaplan HS: Herpes zoster and varicella infections in children with Hodgkin’s disease: An analysis of contributing factors. Cancer 41(l):95–99, 1978.

    CAS  PubMed  Google Scholar 

  67. Bishop JF, Schimpff SC, Diggs CH, Wiernik PH: Infections during intensive chemotherapy for non-Hodgkin’s lymphoma. Ann Intern Med 95(5):549–555, 1981.

    CAS  PubMed  Google Scholar 

  68. Shaikh BS, Lombard RM, Appelbaum PC, Bentz MS: Changing patterns of infections in patients with multiple myeloma. Oncology 39(2):78–82, 1982.

    CAS  PubMed  Google Scholar 

  69. Twomey JJ: Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 132(4):562–565, 1973.

    Article  CAS  PubMed  Google Scholar 

  70. Levine AM, Overturf GD, Field RF, Holdorf D, Paganini-Hill A, Feinstein DI: Use and efficacy of pneumococcal vaccine in patients with Hodgkin disease. Blood 54(5):1171–1175, 1979.

    CAS  PubMed  Google Scholar 

  71. Weibel RE, Vella PP, McLean AA, Woodhour AF, Davidson WL, Hilleman MR: Studies in human subjects of polyvalent pneumococcal vaccines (39894). Proc Soc Exp Biol Med 156(1):144–150, 1977.

    CAS  PubMed  Google Scholar 

  72. Folland D, Armstrong D, Seides S, Blevins A: Pneumococcal bacteremia in patients with neoplastic disease. Cancer 33(3):845–849, 1974.

    CAS  PubMed  Google Scholar 

  73. Hughes WT, Armstrong D, Bodey GP, et al: From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161(3):381–396, 1990.

    CAS  PubMed  Google Scholar 

  74. Nauseef WM, Maki DG: A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 304 (8):448–453, 1981.

    CAS  PubMed  Google Scholar 

  75. Pizzo PA, Levine AS: The utility of protected-environment regimens for the compromised host: A critical assessment. Prog Hematol 10:311–332, 1977.

    CAS  PubMed  Google Scholar 

  76. Rodriguez V, Bodey GP, Freireich EJ, McCredie KB, Gutterman JU, Keating MJ, Smith TL, Gehan EA: Randomized trial of protected environment-Prophylactic antibiotics in 145 adults with acute leukemia. Medicine 57(3):253–266, 1978.

    CAS  PubMed  Google Scholar 

  77. Rhame FS, Streifel AJ, Kersey JH Jr, McGlave PB: Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med 76(5A):42–52, 1984.

    CAS  PubMed  Google Scholar 

  78. Schimpff SC, Greene WH, Young VM, Fortner CL, Cusack N, Block JB, Wiernik PH: Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 82(3):351–358, 1975.

    CAS  PubMed  Google Scholar 

  79. Young LS: Trimethoprim-sulfamethoxazole and bacterial infections during leukemia therapy. Ann Intern Med 95(4):508–509, 1981.

    CAS  PubMed  Google Scholar 

  80. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. J Infect Dis 150(3):372–379, 1984.

    Google Scholar 

  81. Weiser B, Lange M, Fialk MA, Singer C, Szatrowski TH, Armstrong D: Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Ann Intern Med 95(4):436–438, 1981.

    CAS  PubMed  Google Scholar 

  82. Wade JC, de Jongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC: Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: Trimethoprim-sulfamethoxazole vs. nalidixic acid. J infect Dis 147(4):624–634, 1983.

    CAS  PubMed  Google Scholar 

  83. Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J: Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med 95(5):555–559, 1981.

    CAS  PubMed  Google Scholar 

  84. Wells CL, Podzorski RP, Peterson PK, Ramsay NK, Simmons RL, Rhame FS: Incidence of trimethoprim-sulfamethoxazole-resistant enterobacteriaceae among transplant recipients. J Infect Dis 150 (5):699–706, 1984.

    CAS  PubMed  Google Scholar 

  85. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A: Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 102 (1):125–133, 1983.

    CAS  PubMed  Google Scholar 

  86. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L: Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316(26):1627–1632, 1987.

    CAS  PubMed  Google Scholar 

  87. Young LS: Antimicrobial prophylaxis against infection in neutropenic patients. J Infect Dis 147(4):611–614, 1983.

    CAS  PubMed  Google Scholar 

  88. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106(l):1–7, 1987.

    CAS  PubMed  Google Scholar 

  89. Young LS: The new fluorinated quinolones for infection prevention in acute leukemia. Ann Intern Med 106(1):144–146, 1987.

    CAS  PubMed  Google Scholar 

  90. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne delľAdulto. Ann Intern Med 115(1):7–12, 1991.

    Google Scholar 

  91. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 23(4):795–805, 1996.

    CAS  PubMed  Google Scholar 

  92. Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 16(3): 1179–1187, 1998.

    CAS  PubMed  Google Scholar 

  93. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851, 1992.

    CAS  PubMed  Google Scholar 

  94. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis 28(2):250–255, 1999.

    CAS  PubMed  Google Scholar 

  95. Rotstein C, Bow EJ, Laverdiere M, Loannou S, Carr D, Moghaddam N: Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28(2):331–340, 1999.

    CAS  PubMed  Google Scholar 

  96. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325(18):1274–1277, 1991.

    CAS  PubMed  Google Scholar 

  97. Calandra T, Cometta A: Antibiotic therapy for gram-negative bacteremia. Infect Dis Clin North Am 5(4):817–834, 1991.

    CAS  PubMed  Google Scholar 

  98. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328(18):1323–1332, 1993.

    Article  CAS  PubMed  Google Scholar 

  99. Pizzo PA, Hathorn JW, Hiemenz J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315(9): 552–558, 1986.

    CAS  PubMed  Google Scholar 

  100. Behre G, Link H, Maschmeyer G, Meyer P, Paaz U, Wilhelm M, Hiddemann W: Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 76(2):73–80, 1998.

    Article  CAS  PubMed  Google Scholar 

  101. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto Infection Program. Antimicrob Agents Chemother 40(5):1108–1115, 1996.

    CAS  PubMed  Google Scholar 

  102. Feld R: Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: Pros and cons. Clin Infect Dis 29(3):503–507, 1999.

    CAS  PubMed  Google Scholar 

  103. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27(3):603–618, 1998.

    CAS  PubMed  Google Scholar 

  104. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340(10):764–771, 1999.

    Article  CAS  PubMed  Google Scholar 

  105. Kauffman CA, Bradley SF, Ross SC, Weber DR: Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med 91(2):137–141, 1991.

    Article  CAS  PubMed  Google Scholar 

  106. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, et al: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91(2):142–150, 1991.

    Article  CAS  PubMed  Google Scholar 

  107. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10(2):316–322, 1992.

    CAS  PubMed  Google Scholar 

  108. Rolston KV: New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3): 515–521, 1999.

    CAS  PubMed  Google Scholar 

  109. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H: Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341(5):312–318, 1999.

    Article  CAS  PubMed  Google Scholar 

  110. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051, 2000.

    CAS  PubMed  Google Scholar 

  111. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325(21):1453–1460, 1991.

    CAS  PubMed  Google Scholar 

  112. Strumia MM: The effect of leukocytic cream injections in the treatment of neutropenias. Am J Med 187:527–544, 1934.

    Google Scholar 

  113. Brecker G, Wilbur KM, Cronkhite EP: Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Proc Soc Exp Biol Med 84:54–56, 1953.

    Google Scholar 

  114. Young LS: Management of infections in leukemia and lymphoma. In Clinical Approach to Infection in the Compromised Host. Plenum Press, New York, 1989, pp. 467–502.

    Google Scholar 

  115. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP: Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrowtransplantation. Transfusion 34(3):226–232, 1994.

    Article  CAS  PubMed  Google Scholar 

  116. Hubel K, Dale DC, Engert A, Liles WC: Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 183(2):321–328, 2001.

    CAS  PubMed  Google Scholar 

  117. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 327(1):28–35, 1992.

    CAS  PubMed  Google Scholar 

  118. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 327(2):99–106, 1992.

    CAS  PubMed  Google Scholar 

  119. Rowe JM: Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections. Clin Infect Dis 26(6):1290–1294, 1998.

    CAS  PubMed  Google Scholar 

  120. Dignani MC, Anaissie EJ, Hester JP, O’Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ: Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 11(10):1621–1630, 1997.

    Article  CAS  PubMed  Google Scholar 

  121. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18(20):3558–3585, 2000.

    CAS  PubMed  Google Scholar 

  122. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314(16): 1006–1010, 1986.

    CAS  PubMed  Google Scholar 

  123. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326(2):107–116, 1992.

    CAS  PubMed  Google Scholar 

  124. Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325(2):110–117, 1991.

    CAS  PubMed  Google Scholar 

  125. Bodey GP, Nies BA, Mohberg NR: Use of gammaglobulins in infection in acute leukemia patients. JAMA 190:1099–1102, 1964.

    CAS  PubMed  Google Scholar 

  126. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325(2):81–86, 1991.

    CAS  PubMed  Google Scholar 

  127. Amantadine: does it have a role in the prevention and treatment of influenza? A National Institutes of Health Consensus Development Conference. Ann Intern Med 92(2 Pt 1):256–258, 1980.

    Google Scholar 

  128. Young LS, Glauser MP: Gram-negative septicemia and septic shock. Infect Dis Clin North Am 5:739–945, 1992.

    Google Scholar 

  129. Jones CE, Alexander JW, Fisher M: Clinical evaluation of Pseudomonas hyperimmune globulin. J Surg Res 14(2):87–96, 1973.

    Article  CAS  PubMed  Google Scholar 

  130. Harvath L, Andersen BR, Zander AR, Epstein RB: Combined preimmunization and granulocyte transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs. J Lab Clin Med 87(5):840–847, 1976.

    CAS  PubMed  Google Scholar 

  131. Young LS, Stevens P, Ingram J: Functional role of antibody against “core” glycolipid of Enterobacteriaceae. J Clin Invest 56(4):850–861, 1975.

    CAS  PubMed  Google Scholar 

  132. Young LS, Gascon R, Alam S, Bermudez LE: Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 11(Suppl 7):S1564–S1571, 1989.

    PubMed  Google Scholar 

  133. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324(7):429–436, 1991.

    CAS  PubMed  Google Scholar 

  134. Greenman RL, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266(8):1097–1102, 1991.

    Article  CAS  PubMed  Google Scholar 

  135. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709, 2001.

    Article  CAS  PubMed  Google Scholar 

  136. Matthay MA: Severe sepsis—A new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344(10): 759–762, 2001.

    Article  CAS  PubMed  Google Scholar 

  137. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ: Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60(2):309–315, 1982.

    CAS  PubMed  Google Scholar 

  138. Raab SO, Hoeprich PD, Wintrobe MM, et al: The clinical significance of fever in acute leukemia. Blood 16:1609–1628, 1960.

    CAS  PubMed  Google Scholar 

  139. Davies SF, Khan M, Sarosi GA: Disseminated histoplasmosis in immunologically suppressed patients. Occurrence in a nonendemic area. Am J Med 64(1):94–100, 1978.

    Article  CAS  PubMed  Google Scholar 

  140. Cox F, Hughes WT: Disseminated histoplasmosis and childhood leukemia. Cancer 33(4):1127–1133, 1974.

    CAS  PubMed  Google Scholar 

  141. Deresinski SC, Stevens DA: Coccidioidomycosis in compromised hosts. Medicine 54:377–395, 1974.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kuzell Institute for Arthritis and Infectious Diseases, Division of Infectious Diseases, California Pacific Medical Center, San Francisco, California, 94115

    Lowell S. Young

  2. Department of Medicine, University of California at San Francisco, San Francisco, California, 94115

    Lowell S. Young

Authors
  1. Lowell S. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Infectious Disease, Brigham & Women’s Hospital, Boston, Massachusetts

    Robert H. Rubin M.D (Associate Director) (Associate Director)

  2. Center for Experimental Pharmacology and Therapeutics, Harvard University-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts

    Robert H. Rubin M.D (Associate Director) (Associate Director)

  3. Kuzell Institute for Arthritis and Infectious Diseases Chief of the Division on Infectious Diseases, Pacific California Medical Center, San Francisco, California

    Lowell S. Young M.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Young, L.S. (2002). Management of Infections in Leukemia and Lymphoma. In: Rubin, R.H., Young, L.S., Van Furth, R. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/0-306-47527-8_15

Download citation

  • DOI: https://doi.org/10.1007/0-306-47527-8_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-46693-9

  • Online ISBN: 978-0-306-47527-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation